ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

AVXL Anavex Life Sciences Corporation

3.44
0.05 (1.47%)
2024年4月27日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Anavex Life Sciences Corporation AVXL NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
0.05 1.47% 3.44 08:48:08
始値 安値 高値 終値 前日終値
3.40 3.37 3.48 3.44 3.39
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2618:45PRNUSMay 13, 2024 Deadline: Contact The Gross Law Firm to Join..
2024/4/1918:45PRNUSContact The Gross Law Firm by May 13, 2024 Deadline to Join..
2024/4/1618:45PRNUSThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff..
2024/4/1218:45PRNUSClass Action Filed Against Anavex Life Sciences Corporation..
2024/4/1120:30GLOBEAnavex Life Sciences to Present at the Noble Capital Markets..
2024/4/0918:45PRNUSClass Action Filed Against Anavex Life Sciences Corporation..
2024/4/0518:45PRNUSAnavex Life Sciences Corporation Class Action: The Gross Law..
2024/4/0218:45PRNUSShareholders that lost money on Anavex Life Sciences..
2024/3/2918:45PRNUSLost Money on Anavex Life Sciences Corporation(AVXL)? Join..
2024/3/2618:45PRNUSInvestors who lost money on Anavex Life Sciences..
2024/3/2520:30GLOBEAnavex Life Sciences to Present at the 23rd Annual Needham..
2024/3/2218:45PRNUSAVXL LAWSUIT ALERT: The Gross Law Firm Notifies Anavex Life..
2024/3/1820:30GLOBEAnavex Life Sciences Initiates Placebo-Controlled U.S. Phase..
2024/2/2621:30GLOBEAnavex Life Sciences to Present at the 44th Annual TD Cowen..
2024/2/2320:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2320:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2320:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2320:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/2320:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/2/0806:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/2/0721:30GLOBEAnavex Life Sciences Reports Fiscal 2024 First Quarter..
2024/2/0121:30GLOBEAnavex Life Sciences to Announce Fiscal 2024 First Quarter..
2024/1/2607:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/1/2421:30GLOBEAnavex Life Sciences Reports Publication of ANAVEX®3-71 in..
2024/1/1621:30GLOBEAnavex Life Sciences Announces U.S. Phase 2 Clinical Trial..
2024/1/1310:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2024/1/0821:30GLOBEAnavex Life Sciences Announces Grant of U.S. Patent Covering..
2024/1/0321:30GLOBEAnavex to Present at the 42nd Annual J.P. Morgan Healthcare..
2024/1/0222:00GLOBEAnavex Life Sciences Provides an Update on Rett Syndrome..
2023/12/2021:30GLOBEAnavex Announces First Entire Clinical Gene Pathway Data of..
2023/12/1921:30GLOBEAnavex Received Agreement from the Committee for Medicinal..
2023/11/2806:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2023/11/2722:00GLOBEAnavex Life Sciences Reports Fiscal 2023 Year End Financial..
2023/11/2720:29IHMARKETNEWSMonday’s Wall Street Highlights: Walmart, Disney, Lloyds..
2023/11/2422:00GLOBEAnavex Life Sciences to Announce Fiscal 2023 Year End..
2023/11/2222:00GLOBEAnavex Life Sciences Announces Grant of U.S. Patent Covering..
2023/11/2022:00GLOBEAnavex Initiates Regulatory Submission of Oral Blarcamesine..
2023/11/0622:00GLOBEAnavex Life Sciences Appoints Senior VP of Regulatory..
2023/10/2521:00GLOBEAnavex Life Sciences Reports New Publication in Scientific..
2023/9/1420:30GLOBEAnavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in..
2023/9/1220:30GLOBEAnavex Announces Appointment of Dr. Marwan N Sabbagh, MD as..
2023/8/0905:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0820:30GLOBEAnavex Life Sciences Reports Fiscal 2023 Third Quarter..
2023/8/0720:30GLOBEAnavex Life Sciences Reports Publication of ANAVEX®3-71 in..
2023/8/0220:30GLOBEAnavex Life Sciences to Present at the BTIG Virtual..
2023/8/0120:30GLOBEAnavex Life Sciences to Announce Fiscal 2023 Third Quarter..
2023/6/2820:30GLOBELong-term Clinical Study Demonstrates Disease Modifying..
2023/6/2720:30GLOBEAnavex Life Sciences and Partex Group Announce Strategic..
2023/6/2020:30GLOBEAnavex Life Sciences to Present at the H.C. Wainwright 4th..
2023/6/1520:30GLOBEANAVEX®2-73 (blarcamesine) Receives Compassionate Use..

最近閲覧した銘柄

Delayed Upgrade Clock